Source: http://www.google.es/patents/US7901713?dq=flatulence
Timestamp: 2015-07-02 08:13:38
Document Index: 210781383

Matched Legal Cases: ['application No. 60', 'application No. 60', 'application No. 60', 'application No. 60', 'Application No. 02737562', 'Application No. 02784313', 'Application No. 05851567', 'Application No. 05723895', 'Application No. 05723895']

Patente US7901713 - Inhibition of COX-2 and/or 5-LOX activity by fractions isolated or derived ... - Google PatentesB�squeda Im�genes Maps Play YouTube Noticias Gmail Drive M�s »Iniciar sesi�n B�squeda avanzada de patentesPatentesA natural formulation of compounds isolated or derived from hops which inhibit the activity of cyclooxygenase-2 (COX-2) and/or 5-lipoxygenase (5-LOX) is disclosed. The hops formulations may be administered to a mammal to treat or inhibit a pathological condition associated with the activity of COX-2...http://www.google.es/patents/US7901713?utm_source=gb-gplus-sharePatente US7901713 - Inhibition of COX-2 and/or 5-LOX activity by fractions isolated or derived from hops B�squeda avanzada de patentes N�mero de publicaci�nUS7901713 B2Tipo de publicaci�nConcesi�n N�mero de solicitudUS 10/866,315 Fecha de publicaci�n8 Mar 2011 Fecha de presentaci�n10 Jun 2004 Fecha de prioridad20 Jun 2001TarifaPagadasTambi�n publicado comoUS20090118373 N�mero de publicaci�n10866315, 866315, US 7901713 B2, US 7901713B2, US-B2-7901713, US7901713 B2, US7901713B2 InventoresMatthew L. Tripp, Gary K. Darland, Mark Fuller, John G. Babish, Jeffrey S. Bland Cesionario originalMetaproteomics, LlcExportar citaBiBTeX, EndNote, RefManCitas de patentes (100), Otras citas (167), Citada por (3), Clasificaciones (4), Eventos legales (5) Enlaces externos: USPTO, Cesi�n de USPTO, EspacenetInhibition of COX-2 and/or 5-LOX activity by fractions isolated or derived from hops
US 7901713 B2 Resumen
This patent application is a continuation-in-part of U.S. application Ser. No. 10/689,856, filed Oct. 20, 2003, now U.S. Pat. No. 7,270,835, which is a continuation-in-part of U.S. application Ser. No. 10/464,410, filed Jun. 18, 2003, which is a continuation-in-part of U.S. application Ser. No. 10/400,293, filed Mar. 26, 2003 (abandoned), and a continuation-in-part of U.S. application Ser. No. 10/401,283, filed Mar. 26, 2003 (abandoned), both of which claim the benefit under 35 U.S.C. �119(e) to provisional application No. 60/450,237, filed on Feb. 25, 2003, and provisional application No. 60/420,383, filed on Oct. 21, 2002; and is a continuation-in-part of U.S. patent application Ser. No. 10/464,834, filed Jun. 18, 2003, which is a continuation-in-part of U.S. application Ser. No. 10/400,293, filed Mar. 26, 2003 (abandoned), and a continuation-in-part of U.S. application Ser. No. 10/401,283, filed Mar. 26, 2003 (abandoned), both of which claim the benefit under 35 U.S.C. �119(e) to provisional application No. 60/450,237, filed on Feb. 25, 2003, and provisional application No. 60/420,383, filed on Oct. 21, 2002. This application is also a continuation-in-part of U.S. application Ser. No. 09/885,721, filed Jun. 20, 2001, now U.S. Pat. No. 7,205,151. The contents of each of these earlier applications are hereby incorporated by reference as if recited herein in their entirety.
Inhibition of 5-Lipoxygenase Activity by Derivatives of Alpha-Acids from Hops (Humulus lupulus)
Test Materials and Reagents—Standardized (see Table 2) aqueous solutions of fractions isolated or derived from hops (Humulus lupulus) were obtained from BetaTech (Washington, D.C.). The solutions were diluted into DMSO to contain 1 mg/ml of the reference compounds. If necessary, the sample was clarified by centrifugation at 12000�g for 5 minutes. For testing, serial dilutions were made in DMSO. The Lipoxygenase Inhibitor Screening Assay Kit (LISAK) from Cayman (#760700, Chicago, Ill.) was used to assess the effects of test material on lipoxygenase activity. Included with the kit were soybean 15-lipoxygenase (#60700), and linoleic acid. Potato 5-lipoxygenase (#60401) was purchased from Cayman separately. Positive control compounds included caffeic acid (Cayman #70602), Trolox (Sigma 238813) and Rev 5901 (Sigma R5523); these were of the highest purity commercially available. Boswellin (RM07781) was provided by Metagenics, Inc., Gig Harbor, Wash.).
13‡ 17
9.8‡
12‡ 21
11‡ 21
13‡ 27
IC25 † Alphahop
Antioxidant Activity of Hops Fractions
Chemicals and reagents—Bacterial lipopolysaccharide (LPS; B E. coli 055:B5) was from Sigma (St. Louis, Mo.). 6-Carboxy-2′,7′-dichlorofluorescin diacetate (DCFH-DA) was purchased from Molecular Probes Inc. (Eugene, Oreg.); DCFH-DA was dissolved in dimethyl sulfoxide (DMSO) as a stock solution and kept frozen at −20� C. For loading the cells, DCFH-DA from the stock solution was mixed with loading medium (99% RPMI and 1% FBS (fetal bovine serum)) to a final concentration of 20 μM. Standardized aqueous solutions of fractions isolated or derived from hops (Humulus lupulus) were obtained from BetaTech (Washington, D.C.) and are as described in Example 1 Table 1. Positive control compounds included caffeic acid and Trolox obtained from Sigma (St. Louis, Mo.) and were of the highest purity commercially available. Test compounds were dissolved in DMSO to deliver at the maximal concentration in cell cultures of 0.1% (v/v). Unless otherwise noted, all standard reagents were obtained from Sigma and were the purest commercially available.
Cell culture—Jurkat cells (human T cells) were obtained from the American Type Culture Collection (ATCC Number TIB-152, Manassas, Va.) and sub-cultured according to the instructions of the supplier. The cells were routinely cultured at 37� C. with 5% CO2 in RPMI 1640 containing 10% FBS, with 50 units penicillin/mL, 50 μg streptomycin/mL, 5% sodium pyruvate, and 5% L-glutamine.
Cell viability—The CellTiter 96� Aqueous One Solution Cell Proliferation Assay (Promega, Madison, Wis.) was used to assess cellular respiration, as a measure of cell viability, following exposure to the test materials and oxidative stressors. The tetrazolium compound [3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium; MTS] is reduced by NADPH or NADH in living cells into a colored formazan product that is soluble in tissue culture medium. The assay was performed according to the procedure recommended by the manufacturer. MTS reagent was added directly into the microtiter wells, incubated for 1 hour at 37� C. and the absorbance at 490 nm was recorded on a BioTex Instruments ELX-800 microtiter spectrophotometer (Winooski, Vt.). The formazan product as measured at 490 nm is directly proportional to the number of living cells. Cell viability was not affected by the test materials at concentrations used in the assay.
no activity†
Chemicals and reagents—Bacterial lipopolysaccharide (LPS; B E. coli 055:B5) was from Sigma (St. Louis, Mo.). Hops fractions (1) alpha hop (1% alpha acids; AA), (2) aromahop OE (10% beta acids and 2% isomerized alpha acids, (3) isohop (isomerized alpha acids; IAA), (4) beta acid solution (beta acids BA), (5) hexahop gold (hexahydro isomerized alpha acids; HHIAA), (6) redihop (reduced isomerized-alpha acids; RIAA), (7) tetrahop (tetrahydro-iso-alpha acids THIAA) and (8) spent hops were obtained from Betatech Hops Products (Washington, D.C., U.S.A.). The spent hops were extracted two times with equal volumes of absolute ethanol. The ethanol was removed by heating at 40� C. until a only thick brown residue remained. This residue was dissolved in DMSO for testing in RAW 264.7 cells. Unless otherwise noted, all standard reagents were obtained from Sigma (St. Louis, Mo.) and were the purest commercially available. All other chemicals and equipment were as described in Examples 1 and 2 of U.S. patent application publication number 2004/0086580.
Reduced Isomerized Alpha Acids Relieve Headache Pain of Allergies
IAA and RIAA are not COX-1 or COX-2 Enzyme Inhibitors at Physiologically Relevant Levels
The Cayman Chemical COX Inhibitor Screening Assay Kit (CISAK, cat#560131) was used to assess the effect of test materials directly on the activity of both COX-1 and COX-2 enzymes. One mL aliquots of reaction buffer supplied in the kit were placed on a dry bath at 37� C., and 10 μLs of heme and either the COX-1 or COX-2 enzyme were added to the reaction buffer. Twenty μL of test compound were added, followed by a ten-minute incubation. Arachidonic acid was added to initiate the reaction, which was allowed to proceed for 2 minutes. The reaction was stopped by the addition of 56 μL of 1 M HCL, and the resulting PGH2 was reduced to PGF2, by the addition of 100 μL of stannous chloride. The reduced reaction mixture was allowed to sit at room temperature for 5 minutes, and then was refrigerated until used in the EIA assay. Each reaction was performed in duplicate, and each duplicate was plated on the EIA plate twice.
Citas de patentes Patente citada Fecha de presentaci�n Fecha de publicaci�n Solicitante T�tuloUS34518211 Mar 196524 Jun 1969Kalamazoo Spice Extract CoIncreasing the utilization of hops and improving flavor control of malt beverages and the likeUS355297511 Jun 19695 Ene 1971Kalamazoo Spice Extract CoHop flavors for malt beverages and the likeUS372051721 Dic 197013 Mar 1973Hamm T Brewing CoPreparation of a fermented malt champagneUS393260328 May 197113 Ene 1976General Foods CorporationOral preparations for reducing the incidence of dental cariesUS39339194 Mar 197420 Ene 1976Geoffrey WilkinsonHydroformylation of mono-α-olefins and mono-α-acetylenesUS39651883 Ene 197422 Jun 1976Miller Brewing CompanyHop extract process and productUS41235611 Feb 197731 Oct 1978S.S. Steiner, Inc.Method for processing hops for brewingUS41339036 Dic 19769 Ene 1979Siegfried AktiengesellschaftProcess for preparing bitter beveragesUS41488735 Nov 197610 Abr 1979S. S. Steiner, Inc.Method for treating the skin with extracts of hopsUS41548658 Sep 197715 May 1979S. S. Steiner, Inc.Method for processing hops for brewingUS417063811 May 19789 Oct 1979S. S. Steiner, Inc.Method for producing a deodorantUS438942130 Oct 198121 Jun 1983Busch Industrial Products CorporationMethod for controlling light stability in malt beverages and product thereofUS44016841 Oct 198130 Ago 1983Australian Hop Marketers Pty. Ltd.Preservation of hops utilizing ascorbic acidUS44735519 Jun 198325 Sep 1984Faxon Pharmaceuticals, Inc.Anti-inflammatory compositionUS45541702 May 198319 Nov 1985Hop Developments LimitedExtraction of plant material by using carbon dioxideUS46440843 Feb 198617 Feb 1987Miller Brewing CompanyPreparation of tetrahydroisohumulonesUS46922801 Dic 19868 Sep 1987The United States Of America As Represented By The Secretary Of CommercePurification of fish oilsUS475844527 Mar 198619 Jul 1988Hopstabil Hopfenverarbeitungs-Gesellschaft MbhProcess for the production of isohumulonesUS476764011 Abr 198730 Ago 1988Miller Brewing CompanyLight stable hop extracts and method of preparationUS485755417 Ago 198715 Ago 1989Georgios KallimanisMethod for the treatment of psoriasisUS500633714 Abr 19889 Abr 1991Marbert GmbhMedicinal compositions based on spent brewers' grains extract, a process for the preparation thereof, and the use of spent brewers' grains extract for the preparation of cosmetic compositions, and a special brewers' grains extractUS501357131 Ene 19907 May 1991Pfizer Inc.Methods for making tetrahydroisoalpha and hexahydroisoalpha acidsUS504130030 Abr 199020 Ago 1991Kalamazoo Holdings, Inc.Hop flavor which is odor forming impurity freeUS507339611 May 198917 Dic 1991Kalamazoo Holdings, Inc.Beer flavored with a non-acidic hop-flavor fractionUS508297526 Feb 199021 Ene 1992Kalamazoo Holdings, Inc.Synthesis of hexahydrolupulone, novel forms thereof, and its use as a selective inhibitor of cell growth and multiplicationUS51552769 Sep 199113 Oct 1992Hopstabil Hopfenverarbeitungs GmbhProcess for the isomerization of humulone in a carbon dioxide-hops extract and a process for the isolation of isohumulone from itUS51664495 Jun 199124 Nov 1992Kalamazoo Holdings, Inc.Synthesis of hexahydrolupulone, novel forms thereof, and its use as a selective inhibitor of cell growth and multiplicationUS526423615 Oct 199123 Nov 1993Sumitomo Seika Chemicals Co.Method for production of hop extracts and hop extracts obtained therebyUS528650629 Oct 199215 Feb 1994Bio-Technical ResourcesInhibition of food pathogens by hop acidsUS529663731 Dic 199222 Mar 1994Kalamazoo Holdings, Inc.Production of odor-free tetrahydroisohumulates from alpha acids via their tetrahydrohumulates and subsequent isomerizationUS537086316 Dic 19926 Dic 1994Miller Brewing CompanyOral care compositions containing hop acids and methodUS538742513 Ago 19937 Feb 1995Rhone-Poulenc Specialty Chemicals Co.Method and composition for enhancing foam properties of fermented malt beveragesUS560426310 Abr 199518 Feb 1997Hoechst Japan LimitedTreating osteoporosis with humulonesUS564151722 Jul 199324 Jun 1997Drymed AsComposition comprising fertilized shell eggsUS582789520 Sep 199627 Oct 1998Regents Of The University Of MinnesotaHexahydrolupulones useful as anticancer agentsUS58661629 Abr 19972 Feb 1999Smithkline Beecham P.L.C.Pharmaceutical composition containing a drug/β-cyclodextrin complex in combination with an acid-base coupleUS591981313 Mar 19986 Jul 1999Johns Hopkins University, School Of MedicineUse of a protein tyrosine kinase pathway inhibitor in the treatment of diabetic retinopathyUS59685394 Jun 199719 Oct 1999Procter & Gamble CompanyMild, rinse-off antimicrobial liquid cleansing compositions which provide residual benefit versus gram negative bacteriaUS602001926 Mar 19961 Feb 2000Miller Brewing CompanyHydrogenation of hop soft resins using CO2US61299074 Ago 199910 Oct 2000Colgate Palmolive CompanyStable hydrogenated lupulone antibacterial oral compositionsUS620059429 Dic 199913 Mar 2001Vital Dynamics, Inc.Breast-enhancing, herbal compositions and methods of using sameUS621070130 Abr 19993 Abr 2001Healthcomm International, Inc.Medical food for treating inflammation-related diseasesUS622487111 Mar 19981 May 2001Reliv International, Inc.Dietary supplement for nutritionally promoting healthy joint functionUS626499525 Feb 200024 Jul 2001Thomas NewmarkHerbal composition for reducing inflammation and methods of using sameUS629148311 Feb 199818 Sep 2001National Institute Of ImmunologyMethods for prevention and treatment of septic shockUS63835274 Mar 19997 May 2002Nps Pharmaceuticals, Inc.Compositions comprising valerian extracts, isovaleric acid or derivatives thereof with a NSAIDUS63913465 Abr 200121 May 2002Thomas NewmarkAnti-inflammatory, sleep-promoting herbal composition and method of useUS64404651 May 200027 Ago 2002Bioderm, Inc.Topical composition for the treatment of psoriasis and related skin disordersUS644776220 Ene 200010 Sep 2002Colomer Group Spain, S.L.Hair lotion useful for treatment of hair loss and stimulating hair growthUS648245616 Jun 200019 Nov 2002Suntory LimitedMethod for producing low acid beverageUS649242914 Sep 200010 Dic 2002N.V. NutriciaComposition for the treatment of osteoarthritisUS658332225 Feb 200024 Jun 2003Kalamazoo Holdings, Inc.Dihydro and hexahydro isoalpha acids having a high ratio of trans to cis isomers, production thereof, and products containing the sameUS668938830 Oct 200110 Feb 2004Lipoprotein Technologies, Inc.Microencapsulated delivery system for high viscosity fluidsUS67904593 Nov 200014 Sep 2004Andrx Labs, LlcMethods for treating diabetes via administration of controlled release metforminUS680186015 Feb 19995 Oct 2004Genetics Institute, LlcCrystal structure of cPLA2 and methods of identifying agonists and antagonists using sameUS71445909 Ene 20035 Dic 2006Lipoprotein Technologies, Inc.Bioactive compositions derived from humulus lupulusUS719578520 Jun 200227 Mar 2007Metaproteomics, LlcComplex mixtures exhibiting selective inhibition of cyclooxygenase-2US720515120 Jun 200117 Abr 2007Metaproteomics, LlcComplex mixtures exhibiting selective inhibition of cyclooxygenase-2US727083520 Oct 200318 Sep 2007Metaproteomics, LlcCompositions that treat or inhibit pathological conditions associated with inflammatory responseUS727918513 Nov 20049 Oct 2007Metaproteonics, LlcCurcuminoid compositions exhibiting synergistic inhibition of the expression and/or activity of cyclooxygenase-2US733218524 Oct 200219 Feb 2008Metaproteomics, LlcComplex mixtures exhibiting selective inhibition of cyclooxygenase-2US743194812 Abr 20067 Oct 2008Metaproteomics, LlcCompositions that treat or inhibit pathological conditions associated with inflammatory responseUS2002002885218 May 20017 Mar 2002Geetha GhaiResveratrol analogs for prevention of diseaseUS2002007645231 Jul 200120 Jun 2002Ashni Naturaceuticals, Inc.Combinations of sesquiterpene lactones and ditepene lactones or triterpenes for synergistic inhibition of cyclooxygenase-2US2002007729931 Jul 200120 Jun 2002Babish John G.Combinations of sesquiterpene lactones and ditepene triepoxide lactones for synergistic inhibition of cyclooxygenase-2US2002008606230 Oct 20014 Jul 2002Kuhrts Eric HauserMicroencapsulated delivery system for high viscosity fluidsUS2002008607017 Oct 20014 Jul 2002Kuhrts Eric HauserAnti-inflammatory and connective tissue repair formulationsUS200201560876 Sep 200124 Oct 2002Nuss John M.Inhibitors of glycogen synthase kinase 3US2003000321213 Jun 20012 Ene 2003Givaudan SaTaste modifiersUS2003000802120 Jun 20019 Ene 2003Ashni Naturaceuticals, Inc.Complex mixtures exhibiting selective inhibition of cyclooxygenase-2US200300358518 Feb 200220 Feb 2003Sophie ChenAnti-cancer agents and method of use thereofUS2003007731310 May 200124 Abr 2003Robert SchwartzAnti-stress composition intended for incorporation mainly in nutritional vehiclesUS2003009602725 Oct 200222 May 2003Babish John G.Curcuminoid compositions exhibiting synergistic inhibition of the expression and/or activity of cyclooxygenase-2US2003011339324 Oct 200219 Jun 2003Babish John G.Complex mixtures exhibiting selective inhibition of cyclooxygenase-2US2003013395830 Sep 200217 Jul 2003Noriyasu KunoExternal agent for the skin and whitening agentUS2003018040222 Mar 200225 Sep 2003Unigen Pharmaceuticals, Inc.Isolation of a dual COX-2 and 5-lipoxygenase inhibitor from AcaciaUS200302283696 May 200211 Dic 2003Kuhrts Eric HauserProcess for conversion of high viscosity fluids and compositions thereofUS200400729008 Jul 200315 Abr 2004Nps PharmaceuticalsTreating a variety of pathological conditions, including spasticity and convulsions, by effecting a modulation of CNS activity with isovaleramide, isovaleric acid, or a related compoundUS2004008658018 Jun 20036 May 2004Tripp Matthew L.Synergistic compositions that treat or inhibit pathological conditions associated with inflammatory responseUS2004011529018 Jun 200317 Jun 2004Tripp Matthew L.Modulation of inflammation by hops fractions and derivativesUS200401370969 Ene 200315 Jul 2004Kuhrts Eric H.Anti-inflammatory cyclooxygenase-2 selective inhibitorsUS2004015179220 Oct 20035 Ago 2004Tripp Matthew L.Compositions that treat or inhibit pathological conditions associated with inflammatory responseUS200402192405 Feb 20044 Nov 2004Babish John G.Anti-inflammatory pharmaceutical compositions for reducing inflammation and the treatment or prevention of gastric toxicityUS2005004231720 Jun 200224 Feb 2005Babish John GComplex mixtures exhibiting selective inhibition of cyclooxygenase-2US2005012979113 Nov 200416 Jun 2005Babish John G.Curcuminoid compositions exhibiting synergistic inhibition of the expression and/or activity of cyclooxygenase-2US2005019137527 Feb 20041 Sep 2005Babish John G.Synergistic anti-inflammatory pharmaceutical compositions and related methods using curcuminoids or methylxanthinesUS2005019235627 Feb 20041 Sep 2005Babish John G.Synergistic anti-inflammatory pharmaceutical compositions and methods of useUS2006012751130 Ene 200615 Jun 2006Tripp Matthew LModulation of inflammation by hops fractions and derivativesUS2006012751230 Ene 200615 Jun 2006Tripp Matthew LModulation of inflammation by hops fractions and derivativesUS2006012751330 Ene 200615 Jun 2006Tripp Matthew LSynergistic compositions that treat or inhibit pathological conditions associated with inflammatory responseUS2006012751430 Ene 200615 Jun 2006Tripp Matthew LSynergistic compositions that treat or inhibit pathological conditions associated with inflammatory responseUS2006012751530 Ene 200615 Jun 2006Tripp Matthew LSynergistic compositions that treat or inhibit pathological conditions associated with inflammatory responseUS2006012751630 Ene 200615 Jun 2006Tripp Matthew LModulation of inflammation by hops fractions and derivativesUS2006012751730 Ene 200615 Jun 2006Tripp Matthew LSynergistic compositions that treat or inhibit pathological conditions associated with inflammatory responseUS2006019393312 Abr 200631 Ago 2006Tripp Matthew LModulation of inflammation by hops fractions and derivativesUS2006023390214 Feb 200319 Oct 2006Kirin Beer Kabushiki KaishaCompositions and foods for improving lipid metabolismUS2007000364612 Jun 20064 Ene 2007Kuhrts Eric HMethods of administering anti-inflammatory cyclooxygenase-2 selective inhibitorsUS200700203526 Ene 200625 Ene 2007Matthew TrippTreatment modalities for autoimmune diseasesUS2007016069220 Oct 200312 Jul 2007Tripp Matthew LCompositions that treat or inhibit pathological conditions associated with inflammatory responseDE19939350A1 *19 Ago 199922 Feb 2001Plantextrakt Gmbh & Co KgXanthohumol containing hop extract, useful as additive for beer and non-alcoholic drinks and for treatment of cancers* Citada por examinadorOtras citasReferencia1"Information on arthrotrimtm product", downloaded from Internet Aug. 30, 2002.2"Information on Hops and Beer Flavours", downloaded from internet Feb. 15, 2005.3"Information on Zyflamend and Zyflamend PM", downloaded from Internet Aug. 30, 2002.4Abel-salam et al., Pharmacological Research, England 47(4), pp. 311-340 (Apr. 2003).5Albal, MV., et al., "Clinical evaluation of berberine in mycotic infections." Indian J. Ophthalmol 34:91-2 (1986).6Anto, et al. Pharm. Pharmacol. Comm. 4:103-106 (1998).7Anto, et al., "Anti-inflammatory Activity of Natural and Synthetic Curcuminoids", Pharmacy and Pharmacology Communications, 4(2), pp. 103-106 (1998).8Baldermann et al., J. Chromatography A 1192(1):191-3 (May 23, 2008) (Epub Apr. 8, 2008); abstract only (1 page).9Bermejo, et al. Rev. Esp Enferm. Dig. 95: 621-624 and 625-628 (2003).10Bermejo, et al. Rev. Esp. Enferm. Dig. 95(9): 621-624 and 625-628 (2003).11Bolick D et al., Endocrinology 144(12), pp. 5227-5231 (Dec. 2003).12Brown, et al. J. Chem. Soc. 545 (1959).13Byrne, et al. J. Chem. Soc. (c):2810 (1971).14Carroccio, et al. Clin. Chem. 49(6):861-867 (2003).15Carroccio, et al. Clin. Chem. 49:861-867 (2003).16Carson, j. Am. Chem. Soc. 73:1850-1851 (1951).17Chandra, et al. Indian J. Medical Research 60(1):138-142 (1972).18Chandra, et al., "Anti-inflammatory and Anti-Arthritic Activity of Volatile Oil of Curcuma Longa (Haldi)", Indian Journal of Med. Research, vol. 60, No. 1, 1972, 138-142.19Charlier, et al. Eur. J. Med. Chem. 38:645-659 (2003).20Chattopadhyay et al., Current Science, 87(1) (Jul. 10, 2004).21Chen Wei-Jen et al., Journal of Agricultural and Food Chemistry 52(1), pp. 55-64 (Jan. 1, 2004).22Chou et al. Eur. J. Biochem. 115:207-216 (1981).23Chou, et al, J. Theor. Biol. 35:285-297 (1972).24Chou, et al. Adv enzyme regul 22:27-55 (1983).25Chou, et al. Adv enzyme regul 22:27-55 (1984).26Chou, et al. Eur. J. Biochem. 115:207-216 (1981).27Chou, et al. J. Biol. Chem. 252(18):6438-6442 (1977).28Chou, et al. J. Biol. Chem. 252:6438-6442 (1977).29Chou, et al. Trends Pharm. Sci. 4:450-454 (1983).30Chou, et al., TIPS, pp. 450-454, Nov. 1983.31Chou, j. Theor. Biol. 59:253-276 (1976).32Cohen, Protein Kinases-the major drug targets of the twenty-first century? Nature Reviews, 1: 309-315 (2002).33Cohen, Protein Kinases—the major drug targets of the twenty-first century? Nature Reviews, 1: 309-315 (2002).34Costa, et al. Digest. Liver Dis. 35:642-647 (2003).35Davies, WL. Abstract-Fertiliser, Feeding Stuffs and Farm Supplies J. 11:694 (1926).36Davies, WL. Abstract—Fertiliser, Feeding Stuffs and Farm Supplies J. 11:694 (1926).37Davis, WL. Abstract-Fertiliser, Feeding stuffs and Farm Supplies J. 11:694 (1926).38Davis, WL. Abstract—Fertiliser, Feeding stuffs and Farm Supplies J. 11:694 (1926).39De Keukeleire "Fundamentals of Beer and Hop Chemistry" Quimica Nova, 23(1) pp. 108-112 (2000).40Ding, et al. Biochem. Biophy. Res. Comm. 261:218-223 (1999).41English Translation of cover page, pp. 1-2, tables on pp. 30, 78, 122, and p. 142 of reference C59 (Kaltner, D., Untersuchungen zur Ausbildung des Hopfenaromas und technologische MaBnahmen zur Erzeugung hopfenaromatischer Biere, Technische Universitat Munchen, (Nov. 30, 2000), pp. 1-193, plus Tabs. AH1-AH31.) filed on Sep. 17, 2007. See also Reference C63 regarding same.42EP Search Report for EP App. No. 07809709.4.43European Search Report EP 05 723 839.6.44European Search Report for corresponding EP Application No. 02737562.5 (4 pages).45European Search Report for related European Application No. 02784313.5.46Exercise as Treatment for Arthritis, Rheumatic and Immunologic Diseases, Cleveland Clinic, www.clevelandclinic.org, 2007.47Exercise as Treatment for Arthritis, Rheumatic and Immunologic Diseases, Cleveland Clinic, www.clevelandclinic.org, Mar. 14, 2000.48Extended European Search Report EP 07717798.8.49Extended European Search Report EP 07809708.6.50Extended European Search Report EP 10162893.1.51Foucault et al., J. Chromatography A 808(1-2):3-22 (May 29, 1998); abstract only (3 pages).52Friedman, et al. J Cutan Med. Surg. 6(5):449-459 (2002).53Gao et al., J. Food Sci. Nutr. vol. 9, pp. 240-244 (2004).54Gerhauser, Beer Constituents as Potential Cancer Chemopreventive Agents, EP Journal of Cancer 41; 1941-1954: (2005).55Germany, "The Absolutely German Drink," contents of beer, 2004, 5 pages.56Gilani, "Studies on Antihypertensive and Antispasmodic Activities of Methanol Extract of Acacia nilotica Pods", Phytotherapy Research 13: 665-669 (1999).57Goldstein, et al. Am. J. Gastroenterol. 96(4):1019-1027 (2001).58Goldstein, et al. Am. J. Gastroenterol. 96:1019-1027 (2001).59Halter, et al. Gut 49:443-453 (2001).60Hamber, et al. J. Bio. Chem. 246:6713-6721 (1971).61Hamberg, et al. J. Bio. Chem. 246(22):6713-6721 (1971).62Huang, et al. Cancer Res. 51:813-819 (1991).63Information on "Hops and Beer Flavours", IOB Technical Symposium, Apr. 2001, pp. 1-9.64Information on "Zyflamend and Zyflamend PM", downloaded from Internet Aug. 30, 2002.65Information on ArthroTrimTM product', downloaded from Internet Aug. 30, 2002.66International Search Report for Corresponding PCT Application No. PCT/US05/41018; 2pp.67International Search Report for PCT /US06/30920, Aug. 3, 2007, 3 pages.68International Search Report for PCT/US02/19617.69International Search Report for PCT/US04/16043.70International Search Report for PCT/US06/47196.71Jach, Przegl Dermatol. 65(4):379-381 (1978).72Jach, Przegl Dermatol. 65(4):379-382 (1978).73Jafri et al., Pakistan Journal of Science, vol. 61, No. 4, pp. 220-222 (Dec. 2009).74Kaltner, D., Untersuchungen zur Ausbildung des Hopfenaromas and technologische MaBnahmen zur Erzeugung hopfenaromatischer Biere, Technische Universitat Munchen, (Nov. 30, 2000), pp. 1-193, plus Tabs. AH1-AH31.75Kaltner, Investigation of formation of Hops Aroma and technological Measures for Products of Hops-Aromatic Beers, Technical University of Munich, 7 pp. corresponding to Kaltner, D., Technische Universitat Munchen, (Nov. 30, 2000), pp. 1-193, plus Tabs. AH1-A.76Kanematsu, et al. J Bone Miner Res 12(11):1789-1796 (1997).77Konda, et al., Arthritis & Rheumatism 62(6): 1683-1692, (2010).78Lamy Virginie et al., Apoptosis, an Int'l Journal on Programmed Cell Death,13(10), pp. 1232-1242 (Aug. 25, 2008).79Lamy Virginie et al., Carcinogenesis, 28(7), pp. 1575-1581 (Jul. 2007).80Lerman et al, FASEB Journal, Fed. Of American Soc. For Experimental Biol., vol. 18, No. 4-5 (Jan. 1, 2004).81Lopes, Curr. Med Res Opin. 8(3):145-149 (1982).82Lopes, Curr. Med Res Opin. 8:145-149 (1982).83Mannering et al., Food, Nutrition and Chemical Toxicity X(X), pp. 311-323 (Jan. 1, 1993).84Meling, et al. Scand. J. Gastroenterol. 31:339-344 (1996).85Minich et al., Journal of nutrition and Metabolism, vol. 2010, article ID 467316, pp. 1-11, (2010).86Newark, et al., "Beyond Aspirin", pp. 147-151, Hohm Press (2000).87Noreen, et al. J. Nat. Prod 61:2-7 (1998).88Office Action issued for U.S. Appl. No. 11/667,614 mailed Apr. 16, 2010.89Office Action issued for U.S. Appl. No. 11/667,615 mailed Mar. 16, 2010.90Office Action issued for U.S. Appl. No. 11/701,583 mailed Feb. 8, 2008.91Office Action issued for U.S. Appl. No. 11/701,583 mailed Jul. 6, 2009.92Office Action issued for U.S. Appl. No. 11/701,583 mailed Nov. 26, 2008.93Office Action issued in U.S. Appl. No. 10/464,834 on Aug. 3, 2010.94Office Action issued in U.S. Appl. No. 10/532,388 on Mar. 26, 2010.95Office Action issued in U.S. Appl. No. 10/590,301 on Aug. 19, 2010.96Office Action issued in U.S. Appl. No. 10/590,424 on Jun. 29, 2010.97Office Action issued in U.S. Appl. No. 10/789,814 on Jun. 11, 2010.98Office Action issued in U.S. Appl. No. 11/344,552 on Sep. 8, 2010.99Office Action issued in U.S. Appl. No. 11/344,556 on Dec. 16, 2009.100Office Action issued in U.S. Appl. No. 11/344,556 on Mar. 27, 2009.101Office Action issued in U.S. Appl. No. 11/344,556 on Sep. 3, 2010.102Office Action issued in U.S. Appl. No. 11/344,557 on Apr. 21, 2008.103Office Action issued in U.S. Appl. No. 11/344,557 on Aug. 28, 2009.104Office Action issued in U.S. Appl. No. 11/344,557 on Jan. 10, 2007.105Office Action issued in U.S. Appl. No. 11/344,557 on Mar. 25, 2010.106Office Action issued in U.S. Appl. No. 11/344,557 on Sep. 26, 2007.107Office Action issued in U.S. Appl. No. 11/501,393 on Aug. 25, 2010.108Office Action issued in U.S. Appl. No. 11/636,867 on Aug. 30, 2010.109Office Action issued in U.S. Appl. No. 11/649,584 on Mar. 3, 2010.110Office Action issued in U.S. Appl. No. 11/729,696 on Mar. 25, 2010.111Office Action issued in U.S. Appl. No. 12/030,335 on Oct. 21, 2010.112Pairet, et al. Inflamm. Res 47(2), s93-s101 (1998).113Pairet, et al. Inflamm. Res 47, Supplement 2s93-s101 (1998).114Panglisch, monaffsschrift fuer brauwissen schaft, 1990, 43(1), 4-16.115Panglisch, Monafsschrift fuer Brauwissen Schaft, 43(1), 4-16 (1990).116Parts per Milliion, 1 page, 2004.117Pippa, et al. Scand. J. Gastroenterol. Suppl. 167:32-35 (1989).118Plewig, et al. J. Invest. Dermatol. 65(6):532-536 (1975).119Poullis ,et al. J. Gastroenterol. Hepatol. 18:756-762 (2003).120Poullos, et al. J. Gastroenterol. Hepatol. 18:756-762 (2003).121Provital Group, Rosemary-eco Botany, 2007, 9 pages.122Provital Group, Rosemary-eco Botany. 2007 (9 pages).123Q & A, (what does ppm or ppb mean?) 3 pages, 2004.124Rahman, M.M., et al., "Conjugated linoleic acid inhibits osteoclast differentiation of RAW264.7 cells by modulating RANKL signaling" J. Lipid Res., 47(8): 1739-1748, (2006).125Ringbom, et al. J. Nat Prod 61:1212-1215 (1998).126R�seth, digest. Liver Dis. 35:607-609 (2003).127Schjerven, et al. Br. J. Dermatol. 149:484-491 (2003).128Shah, et al. Gut 48:339-346 (2001).129Shimamura, et al. Biochem. Biophys. Res. Comm. 289:220-224 (2001).130Shureiqi, et al. Cancer res. 61:6307-6312 (2001).131Sivri, fundam. Clinic. Pharmacol. 18:23-31 (2004).132Smith, et al., Natural Foam Stabilizing and Bittering Compounds Derived From Hops, Journal of the American Society of Brewing Chemists, vol. 56, No. 2, 1998, pp. 52-57.133Stephan T E et al., Biochemical Pharmacology, 55(4), pp. 505-514, (Feb. 15, 1998).134Stevens, Xanthohumol and related Prenylflavonoids from Hops and Beer: To Your Good Health, Science Direct, 2pp (2004).135Subbaramaiah, et al. Cancer Res. 60:2399-2404 (2000).136Suh, et al. Cancer Res 58:717-723 (1988).137Suh, et al. Cancer Res. 58:717-723 (1988).138Supplemental European Search Report for EP 07845228.139Supplementary European Search Report from related EP Application No. 05851567, 8PP.140Supplementary Partial European Search Report for related European Patent Application No. 05723895.8, 5 pages (2007).141Supplementary Partial European Search Report for related European Patent Application No. 05723895.8, dated Apr. 20, 2007, (5 pages) (cited references are enclosed, see C59, C61-C62).142Tagashira M et al., Bioscience, Biotechnology, and Biochemistry, 59(4), pp. 740-742 (Apr. 1995).143Tagashira, et al., Biosci. Biotech. Biochem. 59(4):740-742 (1996).144The national. 3 pages (1999).145Thomas m. Newmark and paul schulick, Beyond Aspirin nature's answer to arthritis, cancer & alzheimer's disease, hohm press (2000) release 7; pp. 147-151, 248.146Tibble, et al. Drugs Today 37(2):85-96 (2001).147Tibble, et al. Drugs Today 37:85-96 (2001).148Tibble, et al. Gut 45:362-366 (1999).149Tobe, et al. Biosci. Biotech. Biochem 61(1):158-159 (1997).150Turmeric: The Ayurvedic Spice of Life, published at www.bioponic.com/pdfs/TurmericAyurveda.pdf (2003).151US News and world report re Palliative Care, 10 pages (2008).152Van Montfrans et al. Inflammatory Signal Transduction in Crohn's Disease and Novel Therapeutic Approaches. Science Direct, Jun. 2, 2002, 20 pages. Biochemical Pharmacology, vol. 64, issues 5-6.153Vanhoenacker, et al., Analysis of iso-alpha-acids and reduced iso-alpha-acids in beer by direct injection and liquid chromatography with ultraviolet absorbance detection or with mass spectrometry, Journal of Chromatography, vol. 1035, No. 1, (Apr. 30, 2004), pp. 53-61.154Vanhoenacker, et al., Journal of Chromatography, vol. 1035, No. 1, (Apr. 30, 2004), pp. 53-61.155Verzele and De Keukeleire (eds.) Chemistry and Analysis of Hop and Beer Bitter Acids: Elsevier, Chapters 6, 8 pages (1991).156Verzele and De Keukeleire (eds.) Chemistry and Analysis of Hop and Beer Bitter Acids; Elsevier, Chapters 5, 20 pages (1991).157Verzele, et al. Chemistry and analysis of hop and beer bitter acids, Developments in food science, 27, pp. 44-51, 88-139 (1991).158Wang, et al. Free Radical Biology & Medicine 27:612-616 (1999).159Ward, et al., Therapeutic Potential of Phosphoinositide 3-Kinase Inhibitors, Chemistry & Biology, vol. 10, 207-210, Mar. 2003.160Warner, et al. Proc Natl Acad Sci USA 96:7563-7568 (1999).161Written Opinion for corresponding PCT Application No. PCT/US05/41018; 3 pp.162Yamamoto, et al. Abstract-Prostaglandins & Other Lipid Mediators 59:1-235 (1999).163Yamamoto, et al. Abstract—Prostaglandins & Other Lipid Mediators 59:1-235 (1999).164Yamamoto, FEBS Letters 465:103-106 (2000).165Yui, et al. Biol. Pharm. Bull. 26(6):753-760 (2003).166Yui, et al. Biol. Pharm. Bull. 26:753-760 (2003).167Zhao Feng et al., Biological and Pharmaceutical Bulletin, 26(1), pp. 61-65 (Jan. 2003). Citada por Patente citante Fecha de presentaci�n Fecha de publicaci�n Solicitante T�tuloUS841017828 Oct 20112 Abr 2013Kindex Therapeutics, LlcCIS 3,4-dihydroxy-2-(3-methylbutanoyl)-5-(3-methylbutyl)-4-(4-methylpentanoyl)cyclopent-2-en-1-derivatives, substantially enantiomerically pure compositions and methodsUS841017914 Mar 20122 Abr 2013Kindex Therapeutics, LlcCis, 3,4-dihydroxy-2-(3-methylbutanoyl)-5-(3-methylbutyl)-4-(4-methylpentanoyl)cyclopent-2-en-1-derivatives, substantially enantiomerically pure compositions and methodsUS882905618 Mar 20139 Sep 2014Kindex Pharmaceuticals, Inc.Cis 3,4-dihydroxy-2-(3-methylbutanoyl)-5-(3-methylbutyl)-4-(4-methylpentanoyl) cyclopent-2-en-1-one derivatives, substantially enantiomerically pure compositions and methodsClasificaciones Clasificaci�n de EE.UU.424/725 Clasificaci�n internacionalA01N65/00 Clasificaci�n cooperativaA61K31/19 Clasificaci�n europeaA61K31/19Eventos legales FechaC�digoEventoDescripci�n2 Jun 2006ASAssignmentOwner name: COMERICA BANK, CALIFORNIAFree format text: SECURITY AGREEMENT;ASSIGNORS:METAGENICS, INC.;METAGENICS FAR EAST, INC.;META PROTEOMICS, L.L.C.;REEL/FRAME:017706/0815;SIGNING DATES FROM 20050531 TO 20060531Free format text: SECURITY AGREEMENT;ASSIGNORS:METAGENICS, INC.;METAGENICS FAR EAST, INC.;META PROTEOMICS, L.L.C.;SIGNING DATES FROM 20050531 TO 20060531;REEL/FRAME:017706/0815Owner name: COMERICA BANK, CALIFORNIAFree format text: SECURITY AGREEMENT;ASSIGNORS:METAGENICS, INC.;METAGENICS FAR EAST, INC.;META PROTEOMICS, L.L.C.;SIGNING DATES FROM 20050531 TO 20060531;REEL/FRAME:017706/081528 Oct 2008ASAssignmentOwner name: METAPROTEOMICS, LLC, CALIFORNIAFree format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:TRIPP, MATTHEW L.;DARLAND, GARY K.;FULLER, MARK;AND OTHERS;REEL/FRAME:021748/0663;SIGNING DATES FROM 20080508 TO 20080601Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:TRIPP, MATTHEW L.;DARLAND, GARY K.;FULLER, MARK;AND OTHERS;SIGNING DATES FROM 20080508 TO 20080601;REEL/FRAME:021748/0663Owner name: METAPROTEOMICS, LLC, CALIFORNIAFree format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:TRIPP, MATTHEW L.;DARLAND, GARY K.;FULLER, MARK;AND OTHERS;SIGNING DATES FROM 20080508 TO 20080601;REEL/FRAME:021748/066315 Oct 2009ASAssignmentOwner name: BANK OF AMERICA, N.A., CALIFORNIAFree format text: SECURITY AGREEMENT;ASSIGNOR:META PROTEOMICS, LLC;REEL/FRAME:023373/0684Effective date: 20091014Owner name: BANK OF AMERICA, N.A.,CALIFORNIAFree format text: SECURITY AGREEMENT;ASSIGNOR:META PROTEOMICS, LLC;US-ASSIGNMENT DATABASE UPDATED:20100223;REEL/FRAME:23373/684Free format text: SECURITY AGREEMENT;ASSIGNOR:META PROTEOMICS, LLC;US-ASSIGNMENT DATABASE UPDATED:20100323;REEL/FRAME:23373/684Free format text: SECURITY AGREEMENT;ASSIGNOR:META PROTEOMICS, LLC;US-ASSIGNMENT DATABASE UPDATED:20100518;REEL/FRAME:23373/684Free format text: SECURITY AGREEMENT;ASSIGNOR:META PROTEOMICS, LLC;US-ASSIGNMENT DATABASE UPDATED:20100525;REEL/FRAME:23373/684Free format text: SECURITY AGREEMENT;ASSIGNOR:META PROTEOMICS, LLC;REEL/FRAME:23373/684Owner name: BANK OF AMERICA, N.A.,CALIFORNIAFree format text: SECURITY AGREEMENT;ASSIGNOR:META PROTEOMICS, LLC;US-ASSIGNMENT DATABASE UPDATED:20100323;REEL/FRAME:23373/684Effective date: 20091014Owner name: BANK OF AMERICA, N.A.,CALIFORNIAFree format text: SECURITY AGREEMENT;ASSIGNOR:META PROTEOMICS, LLC;REEL/FRAME:023373/0684Effective date: 20091014Owner name: BANK OF AMERICA, N.A.,CALIFORNIAFree format text: SECURITY AGREEMENT;ASSIGNOR:META PROTEOMICS, LLC;US-ASSIGNMENT DATABASE UPDATED:20100525;REEL/FRAME:23373/684Effective date: 20091014Owner name: BANK OF AMERICA, N.A.,CALIFORNIAFree format text: SECURITY AGREEMENT;ASSIGNOR:META PROTEOMICS, LLC;US-ASSIGNMENT DATABASE UPDATED:20100223;REEL/FRAME:23373/684Effective date: 20091014Owner name: BANK OF AMERICA, N.A.,CALIFORNIAFree format text: SECURITY AGREEMENT;ASSIGNOR:META PROTEOMICS, LLC;REEL/FRAME:23373/684Effective date: 20091014Owner name: BANK OF AMERICA, N.A.,CALIFORNIAFree format text: SECURITY AGREEMENT;ASSIGNOR:META PROTEOMICS, LLC;US-ASSIGNMENT DATABASE UPDATED:20100518;REEL/FRAME:23373/684Effective date: 2009101426 Oct 2009ASAssignmentOwner name: META PROTEOMICS, LLC, CALIFORNIAFree format text: RELEASE BY SECURED PARTY;ASSIGNOR:COMERICA BANK;REEL/FRAME:023424/0038Effective date: 20091014Owner name: METAGENICS FAR EAST, INC., CALIFORNIAFree format text: RELEASE BY SECURED PARTY;ASSIGNOR:COMERICA BANK;REEL/FRAME:023424/0038Effective date: 20091014Owner name: METAGENICS, INC., CALIFORNIAFree format text: RELEASE BY SECURED PARTY;ASSIGNOR:COMERICA BANK;REEL/FRAME:023424/0038Effective date: 2009101413 Ago 2014FPAYFee paymentYear of fee payment: 4GirarImagen originalP�gina principal de Google - Sitemap - Descargas masivas de USPTO - Pol�tica de privacidad - Condiciones de servicio - Acerca de Google Patentes - Enviar sugerenciasDatos proporcionados por IFI CLAIMS Patent Services